Bifogade filer
KD PR Modus 2024-11-19 ENG
Kurs
+3,03%
Likviditet
0,78 MSEK
Kalender
| Tid* | ||
| 2025-11-14 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | N/A | Årsstämma |
| 2025-04-30 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-14 | 15:00 | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-04-26 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-17 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2022-01-12 | - | Extra Bolagsstämma 2022 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Extra Bolagsstämma 2021 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-16 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2020-06-15 | - | Årsstämma |
| 2020-05-08 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2020-04-30 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-29 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-28 | - | Årsstämma |
| 2019-05-21 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-08 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-10-31 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-10-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-26 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2016-05-25 | - | Årsstämma |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-21 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-05-06 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
| 2014-12-04 | - | Extra Bolagsstämma 2014 |
| 2014-10-21 | - | Kapitalmarknadsdag 2014 |
| 2014-10-21 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-21 | - | Analytiker möte 2014 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-15 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2014-05-14 | - | Årsstämma |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-19 | - | Bokslutskommuniké 2013 |
| 2013-11-21 | - | Kvartalsrapport 2013-Q3 |
| 2013-11-21 | - | Analytiker möte 2013 |
| 2013-08-22 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-15 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2013-05-14 | - | Årsstämma |
| 2013-05-10 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-20 | - | Extra Bolagsstämma 2013 |
| 2013-03-20 | - | Bokslutskommuniké 2012 |
| 2013-03-13 | - | 15-7 2013 |
| 2012-11-22 | - | Kvartalsrapport 2012-Q3 |
| 2012-11-22 | - | Analytiker möte 2012 |
| 2012-08-23 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-24 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
| 2012-05-23 | - | Årsstämma |
| 2012-05-15 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-22 | - | Bokslutskommuniké 2011 |
| 2011-11-29 | - | 15-7 2011 |
| 2011-11-25 | - | Kvartalsrapport 2011-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Finans |
| Industri | Investeringar |
STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company’s largest shareholder. The funding enables Modus to initiate the recently approved phase 2a study in chronic kidney disease.
”Modus Therapeutics research is gaining momentum and with this funding they now have the opportunity to maintain a good pace of development and start the recently approved phase 2a clinical trial," says Viktor Drvota, CEO, Karolinska Development.
Modus Therapeutics, listed on Nasdaq First North Growth Market, is developing the drug candidate sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation, as well as states of anemia, related to chronic inflammation such as kidney disease.
Karolinska Development's direct ownership interest, and indirect ownership interest via KDev Investment, in Modus Therapeutics amounts to 66% and 8%, respectively.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.